Over 60% of oncology trials in the UK fail to meet recruitment timelines, and every 6-month delay adds £3–5M in burn for early-stage biotechs.
The bottleneck is not science. It is the trial operating system.

In 2026, the winners in UK oncology are not the teams with the most elegant molecules or algorithms — they are the ones that master site activation, recruitment velocity, remote evidence capture, and regulator-ready real-world evidence (RWE) as a single, integrated system.

This post maps the UK Oncology Trial Acceleration Stack — and shows how founders can compress timelines without burning cash.

Why this matters now (UK-specific context)

The UK has one of the world’s strongest oncology research infrastructures:

• A unified national health system

• World-class cancer centres

• Central regulators and HTA bodies

Yet most startups still lose 12–30 months navigating:

• NHS site setup and contracting

• Manual patient screening

• Fragmented consent and outcomes data

• Evidence that cannot be reused for MHRA, NICE, or pharma partnerships

The gap is not access.
The gap is orchestration.

The UK Oncology Trial Acceleration Framework

Four layers. One system.
Each layer solves a different failure point — but real acceleration only happens when they are designed together.

1️⃣ Trial Sites

Where oncology timelines usually break first

What this category actually does

This layer determines:

• how fast you get site green-light

• how many eligible patients you can realistically access

• whether your trial becomes a one-site bottleneck or a scalable program

Common founder mistake:
Treating NHS hospitals as “customers” instead of capacity-constrained execution partners.

Key UK Trial Sites & Networks (18)

1. The Royal Marsden NHS Foundation Trust – flagship oncology trials, early-phase leadership

2. University College London Hospitals NHS Foundation Trust – complex oncology + translational trials

3. Guy’s and St Thomas’ NHS Foundation Trust – diverse oncology populations

4. King’s College Hospital NHS Foundation Trust – strong haemato-oncology research

5. The Christie NHS Foundation Trust – Europe’s largest single-site cancer centre

6. Cambridge University Hospitals NHS Foundation Trust – precision oncology focus

7. Oxford University Hospitals NHS Foundation Trust – early clinical development

8. Imperial College Healthcare NHS Trust – imaging-heavy oncology trials

9. Barts Health NHS Trust – large multi-ethnic cohorts

10. Manchester University NHS Foundation Trust – scale and delivery capacity

11. NIHR Clinical Research Network – national site activation backbone

12. NIHR Biomedical Research Centres – discovery-to-clinic bridges

13. Cancer Research UK Centres – integrated academic pipelines

14. Experimental Cancer Medicine Centres Network – early-phase oncology

15. Velindre Cancer Centre – specialist cancer delivery

16. Beatson West of Scotland Cancer Centre – Scottish trial hub

17. Southampton Clinical Trials Unit – protocol execution expertise

18. Northern Centre for Cancer Care – regional oncology access

How to use this layer correctly

• Design protocols around site capacity, not idealized assumptions

• Pre-map contracting + research nurse availability

• Use 2–3 anchor sites, not one “perfect” site

2️⃣ Recruitment Tools

How you avoid waiting 12 months for first-patient-in

What this category actually does

This layer determines:

• whether your cohort assumptions are real

• how fast you move from ethics approval → enrollment

• whether trials stall after the first few patients

Common founder mistake:
Recruitment planning after protocol lock.

Key UK Recruitment & Feasibility Platforms (18)

1. Lindus Health – end-to-end trial execution

2. Huma – decentralised trials

3. TriNetX UK – real-world cohort feasibility

4. IQVIA UK – enterprise recruitment

5. TrialReach – NHS-integrated discovery

6. Antidote – patient-first recruitment

7. Deep 6 AI – automated cohort screening

8. Owkin UK – federated learning for feasibility

9. Castor EDC – flexible trial data

10. Medidata UK – enterprise trial ops

11. Clara Health – oncology trial access

12. Trialbee – digital patient sourcing

13. SubjectWell – participant engagement

14. Cytel – design + analytics

15. Flatiron Health UK – oncology-specific data

16. Tempus UK – molecular cohorts

17. Open Clinical – protocol testing

18. Savana Medical – text-based cohort discovery

How to use this layer correctly

• Run feasibility before ethics

• Align inclusion criteria with real NHS data

• Treat recruitment as data science, not marketing

3️⃣ Remote Monitoring

Why modern oncology trials can’t rely on site visits alone

What this category actually does

This layer captures:

• toxicity signals

• adherence

• quality-of-life outcomes

Common founder mistake:
Adding RPM late, as an “extra feature”.

Key UK-Relevant Monitoring & ePRO Tools (18)

1. Careology – end-to-end cancer care

2. Kaiku Health – validated ePROs

3. Patients Know Best – NHS-integrated records

4. Biofourmis – high-acuity RPM

5. Current Health – continuous vitals

6. Withings Health Solutions – trial-grade wearables

7. AliveCor – cardiotoxicity detection

8. Carevive – patient-reported outcomes

9. Huma RPM – scalable RPM

10. Evidation – longitudinal engagement

11. Adherium – medication compliance

12. Propeller Health – sensor-driven data

13. Health Recovery Solutions – clinical-grade RPM

14. Biobeat – continuous monitoring

15. BrightInsight – FDA/MHRA-ready platforms

16. Medopad – oncology monitoring heritage

17. Philips VitalSuite – enterprise RPM

18. Doccla – NHS-deployed RPM

How to use this layer correctly

• Design ePROs aligned with regulators

• Capture toxicity continuously, not episodically

• Reduce patient burden → higher retention

4️⃣ Evidence Engines

Where trials either create value — or die commercially

What this category actually does

This layer converts:
trial data → MHRA-grade evidence → NICE logic → pharma-usable assets

Common founder mistake:
Assuming “good clinical data sells itself”.

UK Evidence & RWE Infrastructure (18)

1. MHRA – regulatory acceptance

2. NICE – reimbursement logic

3. NHS England – national adoption

4. Genomics England – precision medicine backbone

5. HDR UK – trusted research environments

6. IQVIA Real World Solutions – enterprise RWE

7. Aetion – causal inference

8. Verantos – external comparators

9. COTA Healthcare – outcomes analytics

10. Flatiron Health RWE – trial-grade RWD

11. Tempus Evidence – molecular evidence

12. Health Catalyst – outcome modeling

13. Clarify Health – payer-grade metrics

14. Aridhia – secure analytics

15. DNAnexus – multi-omics data

16. SAS Health – enterprise evidence

17. BC Platforms – population genomics

18. Q Research Software – patient insight analysis

How to use this layer correctly

• Define economic endpoints early

• Design evidence once, reuse everywhere

• Think buyer logic, not publication logic

The Missing Link: Orchestration

Most founders try to “buy tools” for each layer.
The fastest teams design the system first.

That means:

• Aligning protocol design with site capacity

• Locking recruitment feasibility before ethics submission

• Capturing outcomes in formats reusable for MHRA, NICE, and pharma

• Building an evidence narrative that investors can underwrite

This is the gap I work in.

How I help UK oncology teams accelerate

I work as the operating layer between science, sites, vendors, and regulators.

Specifically:

• Designing trial acceleration architectures (not just vendor stacks)

• Mapping site + cohort strategy before trials start

• Translating clinical outcomes into investor- and pharma-grade evidence

• Compressing timelines while protecting runway

If you are running or funding oncology trials in the UK, this is where months — and millions — are saved.